Xinhua Silk Road - Belt and Road Portal, China's silk road economic belt and 21st Century Maritime Silk Road Website Xinhua Silk Road - Belt and Road Portal, China's silk road economic belt and 21st Century Maritime Silk Road Website
Subscribe CustomBlackClose

Belt & Road Weekly Subscription Form

download_pop

Research ReportCustomBlackClose

The full edition of the report is available at Xinhua Silk Road Database. You can click the “Table of Content” to have a general understanding of it.

Click on the button below to create your account and get immediate access to thousands of articles.

Start a Free Trial

Xinhua Silk Road Database
News for Outlets

CanSinoBIO reaches mRNA vaccine deal with AstraZenecaAB

August 09, 2023


Abstract : Chinese vaccine developer CanSinoBIO entered into a product supply framework agreement with AstraZenecaAB, under which CanSinoBIO will provide AstraZenecaAB with development and manufacturing services in support of its mRNA vaccine programme Tuesday, reported Cnr.cn.

BEIJING, Aug. 9 (Xinhua) -- Chinese vaccine developer CanSinoBIO entered into a product supply framework agreement with AstraZenecaAB, under which CanSinoBIO will provide AstraZenecaAB with development and manufacturing services in support of its mRNA vaccine programme Tuesday, reported Cnr.cn.

Featuring simplification of craft, the mRNA technology platform established by CanSinoBIO can shorten the time of product development and rapidly achieve the industrialization of scientific research results. The company has completed the first phase of the mRNA vaccine production base project to support the R&D and commercialization of products based on the mRNA platform.

It is learned that based on CanSinoBIO's extensive experience and technology in developing, manufacturing and commercializing vaccine products, AstraZenecaAB's ongoing development of mRNA vaccines will focus on leveraging the company's mRNA production platform to advance its development of specific vaccines.

CanSinoBIO said that signing of the agreement is an important symbol of the company's ability to be recognized by international pharmaceutical companies, affirming the research and development strength and competitive advantage of CanSinoBIO in the mRNA technology field.

(Edited by Bao Nuomin with Xinhua Silk Road, baonuomin@xinhua.org)

Scan the QR code and push it to your mobile phone

Keyword: vaccine

Write to Us belt & road login close

Do you want to be a contributor to Xinhua Silk Road and tell us your Belt & Road story? Send your articles to [email protected] and share your stories with more people.

Click on the button below to create your account and get im http://img.silkroad.news.cn/templates/silkroad/en2017te access to thousands of articles.

Start a Free Trial

Ask Us A Question belt & road login close

If you have any questions, please enter them in the box below.

Identifying code Reload

Write to Us belt & road login close

Do you want to be a contributor to Xinhua Silk Road and tell us your Belt & Road story? Send your articles to silkroadweekly@xinhua.org and share your stories with more people.

Click on the button below to create your account and get im http://img.silkroad.news.cn/templates/silkroad/en2017te access to thousands of articles.

Start a Free Trial